Lana Kandalaft

faculty photo
Adjunct Assistant Professor of Obstetrics and Gynecology
Director of Translational and Clinical Operations, Ovarian Cancer Research Center, Center for Research on Women's Health and Reproduction, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Department: Obstetrics and Gynecology

Contact information
Privat-Docent, Centre de Thérapies Expérimentales
Département d'oncologie
Université de Lausanne
Lausanne, 19104-6160
Office: 215-573-4782
Fax: 215-573-5129
Education:
GSCE (General Certificate of Secondary Education)
London Examination (honors), 1995.
PharmD
University of Jordan School of Pharmacy, Amman Jordan (cum laude), 2000.
PhD (Pharmaceutical Cell Biology and Drug Delivery)
Welsh School of Pharmacy, Cardiff University, UK, 2003.
MTR (Master of Science in Translational Research)
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2012.
Permanent link
 

Description of Itmat Expertise

Immunotherapy and ovarian cancer

Selected Publications

Chiang C, Coukos G, Kandalaft LE: Whole Tumor Vaccines-Where are we? Vaccines 3, 344-372, Apr 2015 doi:10.3390/vaccines3020344.

Zsiros EZ, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine B, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Feldman M, Tanyi JL, Kandalaft LE, Coukos G: The Ovarian Cancer Chemokine Landscape is Conducive to Homing of Vaccine-promed and CD3/CD28 Costimulated T cells Prepared for Adoptive Therapy. Clin Cancer Res 15;21(12):2840-50, Jun 2015.

Tanyi J, Kandalaft LE, Ophir E, Bobisse, Genolet, R, Zsiros E, Torigian D, Mick, R, Harrari A, Coukos G: Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade elicits antitumor immune response in ovarian cancer,‐ ASCO, Jun 2015.

Ophir E, Bobisse, S, Kandalaft LE, Tanyi J, Genolet, R, Zsiros E, Torigian D, Mick, R, Harrari A, Coukos G: Increased anti-tumor immunity that correlates with clinical benefit and induction of neoantigens reactivity following autologous tumor lysate-pulsed dendritic cells vaccination in recurrent ovarian cancer, CIMT, May 2015.

Chiang C, Balint K, Coukos G, Kandalaft LE: Potential approaches for more successful dendritic cellbased immunotherapy. Expert Opin Biol Ther 2:1-14, Jan 2015.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE: Personalized approaches to active immunotherapy in cancer. Biochim Biophys Acta 1865(1):72-82, Jan 2015.

Zsiros E, Tanyi J, Balint K, Kandalaft LE: Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol 26(5):492-500, Sep 2014.

Tanyi J, Kandalaft LE, Zsiros Z, Mantia-Smaldone G, Coukos G: Combinatorial immunotherapy enhances survival in patients with recurrent ovarian cancer, SGO, Mar 2014.

Kandalaft LE, Chiang C, Tanyi J, Hagemann AR, Motz G, Sovorons N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Czerniecki B, Powell D, Coukos G : A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 1;19(17):4801-15, Sep 2013.

Kandalaft LE, Tanyi J, Coukos G: A Phase I Clinical Trial of Autologous OCDC Vaccine in Recurrent Ovarian Cancer. J Transl Med 18;11(1):149, Jun 2013.

back to top
Last updated: 02/12/2016
The Trustees of the University of Pennsylvania